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Introduction: Glaucoma is a multifactorial disease characterized by progressive optic nerve 
injury and visual field defects. Elevated intraocular pressure (IOP) is the most widely recognized 
risk factor for the onset and progression of open-angle glaucoma, and IOP-lowering medica-
tions comprise the primary treatment strategy. IOP elevation in glaucoma is associated with 
diminished or obstructed aqueous humor outflow. Pharmacotherapy reduces IOP by suppressing 
aqueous inflow and/or increasing aqueous outflow.
Purpose: This review focuses on novel non-FDA approved ocular antihypertensive compounds 
being investigated for IOP reduction in ocular hypertensive and glaucoma patients in active 
clinical trials within approximately the past 2 years.
Methods: The mode of IOP reduction, pharmacology, efficacy, and safety of these new agents 
were assessed. Relevant drug efficacy and safety trials were identified from searches of various 
scientific literature databases and clinical trial registries. Compounds with no specified drug 
class, insufficient background information, reformulations, and fixed-combinations of marketed 
drugs were not considered.
Results: The investigational agents identified comprise those that act on the same targets of 
established drug classes approved by the FDA (ie, prostaglandin analogs and β-adrenergic 
blockers) as well as agents belonging to novel drug classes with unique mechanisms of action. 
Novel targets and compounds evaluated in clinical trials include an actin polymerization inhibi-
tor (ie, latrunculin), Rho-associated protein kinase inhibitors, adenosine receptor analogs, an 
angiotensin II type 1 receptor antagonist, cannabinoid receptor agonists, and a serotonin receptor 
antagonist.
Conclusion: The clinical value of novel compounds for the treatment of glaucoma will 
depend ultimately on demonstrating favorable efficacy and benefit-to-risk ratios relative to 
currently approved prostaglandin analogs and β-blockers and/or having complementary modes 
of action.
Keywords: intraocular pressure, glaucoma progression, clinical trials, drug development, 
aqueous humor dynamics, antihypertensive
Introduction
Glaucoma, characterized by optic nerve head cupping and visual field defects, is a 
common cause of preventable and irreversible blindness worldwide. It is a group of 
ocular conditions in which there is diminished or obstructed outflow of aqueous humor 
from the eye at the iridocorneal angle, leading to progressive damage to the optic nerve 
and loss of visual function. The disease can be divided into two broad categories, 
open-angle and angle-closure (closed-angle) glaucoma, based on the appearance of the 
anterior chamber angle. Open-angle glaucoma has characteristics of an unobstructed Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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and normal iridocorneal angle. In angle-closure glaucoma, 
the anterior chamber angle is occluded by the peripheral 
iris. The open-angle glaucomas range from normal-tension 
glaucoma (NTG; intraocular pressure [IOP] is normal and 
typically 10–21 mm Hg) to primary (or chronic) open-angle 
glaucoma (POAG) with elevated IOP.1,2
Aqueous humor is produced by the ciliary body epithe-
lium and exits the anterior chamber by two main outflow 
pathways, trabecular (conventional) and uveoscleral (uncon-
ventional). Flow in the trabecular pathway is through the 
trabecular meshwork into Schlemm’s canal and aqueous 
veins, whereas the uveoscleral pathway is through the cili-
ary muscle and downstream choroid, sclera, and episcleral 
tissues.3,4 The level of IOP is maintained when the rate of 
aqueous inflow is equal to the rate of aqueous outflow. 
Studies indicate that a certain level of IOP is an important 
causative risk factor for the onset and progression of POAG 
and NTG, therefore treatment is directed at controlling 
IOP.2,5 It is well established that POAG involves reduc-
tions in aqueous humor outflow via the trabecular pathway 
and a cyclical association with increased IOP.6,7 However, 
a role for uveoscleral outflow in glaucoma pathology is 
unclear and researchers are not in accordance.4,6 The com-
plex mechanisms of damage in open-angle glaucoma have 
been extensively reviewed, and thus will not be discussed 
herein.3,6,8–11
Medical treatment is the first choice of therapy for open-
angle glaucoma while laser, surgical peripheral iridotomy, 
or cataract surgery are initial procedures for primary angle-
closure glaucoma, followed by medical therapy. These 
treatments are aimed at lowering IOP since this is important 
for slowing the disease progression. A meta-analysis of 
relevant randomized controlled clinical trials in patients 
with ocular hypertension found that the risk of conversion 
to glaucoma is decreased by 14% with each extra 1 mm Hg 
of IOP reduction.12 Additionally, early detection and indi-
vidualized treatment of glaucoma are needed because of 
its unpredictable progression and inter- and intra-patient 
variability.13 Pharmacotherapy for glaucoma reduces IOP 
by suppressing aqueous inflow and/or increasing aqueous 
outflow. Agents that increase aqueous outflow are desir-
able for the therapy of POAG since the defect associated 
with this disease results in diminished outflow. However, 
identification of novel drug targets has been slow in this 
research area.
In the majority of glaucoma clinical drug trials, reduc-
tion of IOP is the primary efficacy endpoint. For new 
glaucoma drug approvals, the United States Food and Drug 
Administration (FDA) differentiates between the indications 
for IOP-lowering (do not require proof of changes in struc-
tural or functional course of the disease) and glaucoma 
(need to demonstrate effects on the disease process).14 
A critical feature for new drug approvals by the FDA is 
the benefit-to-risk ratio that is determined by drug efficacy 
and health risk assessment from clinical trials in com-
parison to the benchmark drugs.14 Currently, the five FDA 
established pharmacologic classes of IOP-lowering drugs 
are α-adrenergic agonist (eg, brimonidine); β-adrenergic 
blocker (eg, timolol); carbonic anhydrase inhibitor (eg, 
dorzolamide); cholinergic agonist (eg, pilocarpine, carba-
chol); and prostaglandin analog (eg, latanoprost, travoprost, 
bimatoprost).
The aim of this review is to provide information on 
novel compounds in clinical trials that are being actively 
developed for the reduction of IOP in ocular hypertensive 
and glaucoma patients. Although the discussions include the 
mode of IOP reduction in humans and non-human primates, 
pharmacology, efficacy, and safety of these new agents, it is 
with the acknowledgment that available publications may be   
scarce.
Methods
The focus of this review is novel ocular antihypertensive 
compounds that are active in Phases I–III of glaucoma 
clinical trials within the past two years ending in December 
2010. The new compounds comprise those in established 
and novel drug classes. We also mention selected com-
pounds that were discontinued within the last three years, 
and emerging trends among the discussed novel targets. 
Novel drug delivery systems for IOP-lowering agents were 
also assessed. Excluded compounds are those with no 
specified drug class, not enough information or interest, 
reformulations, and fixed-combinations of marketed drugs. 
It is not the intent of this review to provide an exhaustive 
list of agents.
Databases used in the searches included Adis™ R&D 
Insight (Wolters Kluwer Pharma) accessed via OvidSP®, 
IntegritySM (Thomson Reuters), BioPharm Insight™ (Infinata 
Inc), Citeline™ TrialTrove, and Clinical Trial Registry (http://
www.clinicaltrials.gov). Other sources included published 
articles, meeting abstracts, press releases, and company 
web sites (reported as of year-end 2010). Novel ocular 
antihypertensive compounds are summarized in tables as 
follows: established pharmacologic classes (Table 1); novel 
targets (Table 2); discontinued or no longer in development 
(Table 3).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Novel compounds in drug classes  
of FDA standards
An efficacy standard (benchmark) for new IOP-lowering 
agents is equivalency to one of four FDA approved 
  ophthalmic products: timolol maleate, latanoprost, 
  bimatoprost, or travoprost.14 The proposed new agents are 
compared with these standards for reduction of elevated IOP 
as primary therapies or as adjunctive therapies to another 
IOP-lowering drug in a different pharmacologic class. 
Importantly, the benefits of new proposed drugs should 
outweigh the health risks.
Timolol
Timolol (approved in 1978; Merck Frosst) is a β-adrenergic 
blocker that served as the “gold-standard” in glaucoma 
therapy until the introduction of prostaglandin analogs in 
1996. β-adrenergic blockers lower IOP by decreasing aque-
ous humor production (aqueous inflow suppressants). Only 
one novel compound that targets β-adrenergic receptors is 
currently in glaucoma clinical trials. Sylentis is conducting 
a Phase I/II study to establish the efficacy and tolerability of 
topical SYL040012 in patients with ocular hypertension or 
glaucoma (Trial ID: NCT01227291). SYL040012 is a small 
interfering RNA (siRNA) that triggers RNA interference 
(RNAi), an endogenous cellular process in which double-
stranded RNA can cause physiological gene silencing in 
organisms.15 SYL040012 may potentially reduce IOP by 
knockdown of β2-adrenergic receptors. This new pharma-
cological approach appears to be promising for glaucoma 
treatment; however RNAi-based drugs, in general, face 
potential development obstacles such as targeted delivery, 
efficacy, selectivity, and safety.16–18
Latanoprost, travoprost, bimatoprost
Latanoprost (approved in 1996; Pfizer) and travoprost 
(approved in 2001; Alcon) are prostaglandin analogs that act 
as agonists at prostanoid FP receptors. Bimatoprost (approved 
in 2001; Allergan) is a synthetic structural prostaglandin 
analog that mimics the activity of prostaglandin F2α ethanol-
amide, termed prostamide F2α. These ophthalmic drugs lower 
IOP in humans by enhancing aqueous outflow, predominately 
via the uveoscleral pathway with variable increases in outflow 
facility (trabecular pathway).19
Prostaglandins and thromboxanes, collectively referred 
to as prostanoids, are biologically active metabolic products 
of arachidonic acid and other essential fatty acids. Prostanoid 
receptors belong to the cell-surface G protein-coupled 
structural family. The cloned receptors are classified into 
five major types, based on their preferential affinity for the 
endogenous ligands prostaglandin D2 (DP), E2 (EP), F2α 
(FP), I2 (IP), and thromboxane A2 (TP) and its endoperoxide 
precursor PGH2.20
The prostanoid EP receptor has been further divided into 
subtypes that have generally excitatory (EP1, EP3) or inhibi-
tory (EP2, EP4) actions on cell function. Taprenepag isopropyl/
PF-04217329 is a novel prostanoid EP2 receptor agonist. 
Although its mechanism of IOP reduction in humans has not 
been reported, taprenepag may be inferred to enhance uveo-
scleral outflow. This is based on results of another EP2 receptor 
agonist, butaprost, that increases uveoscleral outflow in con-
scious cynomolgus monkeys.21 Pfizer has completed a Phase 
II safety and efficacy clinical trial of taprenepag at escalating, 
once-daily, topical   ophthalmic doses of 0.0025% to 0.03% in 
patients diagnosed with POAG or ocular hypertension (Trial 
ID: NCT00572455). The results showed that taprenepag was 
comparable to   latanoprost 0.005% in IOP reduction, but pro-
duced an increased rate of   treatment-emergent adverse effects 
of mild to severe   photophobia ± iritis at 0.015% and higher 
concentrations.22,23 Taprenepag 0.005%, 0.02%, and 0.03% 
significantly increased corneal thickness compared to baseline 
in at least one eye.22 It is presently unclear whether taprenepag 
may benefit from formulation improvements and lower doses.
Table 1 Novel ocular antihypertensive compounds in established pharmacologic classes
Drug class/Compound Organization Highest development phase Notes
β-Adrenergic blocker
SYL040012 Zeltia/Sylentis Pi/ii β2-adrenergic antagonist – siRNA
Prostaglandin analogs
AR-102; mopidamol Aerie Pii FP agonist
BOL-303259-X; NCX-116;  
PF-03187207
NicOx/Bausch and Lomb Pii Nitric oxide donating PGF2α 
agonist; NicOx and Bausch and 
Lomb partner in 2010
Taprenepag isopropyl;  
PF-04217329
Pfizer Pii eP2 agonist
Abbreviations: siRNA, small interfering RNA.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Only a few non-novel or unspecified   prostaglandin 
agonists are in clinical trials for glaucoma treatment: AR-102 
(FP agonist, Aerie Pharmaceuticals, Phase II, Trial ID: 
NCT00523250) and NCX-116/BOL-303259-X/PF-03187207 
(nitric oxide donating prostaglandin F2α agonist, NicOx SA 
and Bausch and Lomb). Two Phase II trials of the latter 
compound have recently been completed and await pub-
lication (Trial ID: NCT00441883 and NCT00595101); 
an additional randomized single-masked Phase II is cur-
rently recruiting subjects (Trial ID: NCT01223378). Aerie 
Pharmaceuticals discontinued the development of AR-101 
(planned Phase I).
Punctal plugs for drug delivery
Patient adherence to ocular antihypertensive medication 
is a challenge in clinical practice. Ophthalmic drug deliv-
ery systems are among the technological approaches that 
may be effective for adherence to glaucoma medication.24 
Drug-eluting punctal plugs that are being investigated as 
sustained-release drug delivery systems for latanoprost and 
bimatoprost are now in advanced stages of clinical testing. 
The Latanoprost Punctal Plug Delivery System (L-PPDS) is 
an experimental drug-releasing implant designed to   provide 
sustained delivery of latanoprost for the reduction of IOP. 
QLT Plug Delivery has designed the device to deliver 
44 µg or 81 µg latanoprost continuously over a period of 
3 months. A Phase II, randomized, masked, parallel-group 
study evaluating the device in open-angle glaucoma or 
ocular hypertensive patients has been completed (Trial ID: 
NCT00650702) but the results have not yet been published. 
Additional Phase II trials are now in progress (Trial ID: 
NCT00967811, NCT01037036, NCT01229982).
An experimental sustained-release punctal plug for 
the intraocular delivery of bimatoprost is under clinical 
development by Vistakon Pharmaceuticals. The efficacy 
and safety of the bimatoprost punctal plug were   evaluated 
in two   randomized, double-blind, Phase II studies in 
  open-angle glaucoma or ocular hypertensive patients (Trial 
ID: NCT00824720 and NCT01016691). The studies have 
not yet been published, but initial data from one of the trials 
indicate that the device did not significantly lower IOP as 
compared with placebo treatment.
Novel targets
Actin
Actin is a monomeric protein with an ability to spontane-
ously polymerize into helical filaments. The actin filaments 
and other cytoskeletal protein polymers provide eukaryotic 
cells with mechanical structure, mobility, and contribute to 
complex cellular activities.25 Latrunculins are macrolides 
from marine sponges that inhibit actin polymerization 
by sequestering monomeric actin in a highly specific 
manner.26–29 Studies in living non-human primates (cyno-
molgus monkeys) and human enucleated postmortem eyes 
show   latrunculin B increases trabecular outflow by a novel 
mechanism of actin cytoskeleton disruption in cells of the 
conventional pathway.30–33 The increases in outflow may 
involve expansion of the space between the inner wall of 
Schlemm’s canal and the trabecular collagen beams and/or 
increased openings between inner wall cells.32,33
Inspire Pharmaceuticals evaluated INS-115644, a 
latrunculin B compound, in a Phase I, 3-day, twice-daily, 
ascending topical ophthalmic dose (0.005%, 0.01%, 0.02%, 
0.05%) clinical trial to evaluate safety, tolerability, and IOP-
lowering efficacy in patients with ocular hypertension or early 
POAG (Trial ID: NCT00443924). INS-115644 reduced IOP 
only at the 0.02% and 0.05% doses, producing a maximal 
12 hour decrease of 4 mm Hg on day 3 in patients treated 
with the 0.02% dose, and was generally well tolerated.34 
Adverse events included mild ocular redness, irritation, and 
corneal disorder at the two highest doses (0.02%, 0.05%) of 
INS-115644. Inspire also noted a transient, clinically insig-
nificant increase in central corneal thickness of #2.5%.
In preclinical studies, topically applied latrunculin B 
0.005% or 0.01%, twice-daily for 4.5 days, reduced IOP 
by 2.5–2.7 mm Hg (day 1) to 3.2–4.4 mm Hg (day 5) and 
had no overt adverse effects on the corneas of cynomolgus 
  monkeys.35 Compared to human subjects, the non-human 
primates appear to be more responsive to IOP reduction 
by latrunculin B at low doses under the laboratory study 
  conditions. At a higher single topical dose of 0.02% (approxi-
mately), latrunculin B reduced the IOP of ocular normotensive 
cynomolgus monkeys by 3 mm Hg, but had adverse effects 
of small transient increases in corneal thickness, increases 
in corneal endothelial permeability, and anterior chamber 
flare.30 In several topically applied animal   studies, latrunculin 
B was dissolved in a vehicle that contained 25% dimethyl 
sulfoxide (DMSO), due to its low aqueous   solubility.35 Given 
its effects on the cornea, IOP-lowering efficacy, and relative 
insolubility, latrunculin B may benefit from administration 
by novel drug delivery methods.35,36
Rho-associated protein kinase
The Rho family of small guanosine triphosphatases (GTPases) 
has a central role in cellular processes, particularly those 
involving actin cytoskeleton assembly, actin-myosin mediated Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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cell contraction and motility.37,38 ROCK (Rho-associated 
coiled coil-forming protein kinase) is a downstream effector 
of Rho in the Rho-dependent signal transduction pathway.37,39 
Thus, specific inhibitors of ROCK that modulate changes 
in the actin cytoskeleton and cellular motility of the trabe-
cular meshwork, Schlemm’s canal, and ciliary muscle may 
comprise a potential new class of ocular hypotensive drugs 
that enhance aqueous drainage.40–43 ROCK inhibitors may 
lower resistance to aqueous outflow by activities that include 
decreasing myosin light-chain phosphorylation, which leads 
to cellular relaxation in human trabecular meshwork and 
Schlemm’s canal cells.44,45 Finding inhibitors that are selec-
tive for ROCK is a major challenge because different protein 
kinases have structurally similar active binding sites yet 
regulate diverse signaling pathways.46,47 Consequently, it may 
be difficult to attribute the effects of even relatively selec-
tive ROCK inhibitors to ROCK specifically and not to other 
kinases.39,42,48 The safety profile of this class of compounds 
is influenced by its selectivity for inhibiting ROCK as well 
as any effects on relevant ocular tissues, such as changes in 
accommodation, pupil diameter, or hyperemia.41,49
ROCK inhibitors that are currently in clinical trials 
for glaucoma or ocular hypertension include AR-12286 
(Phase II, Aerie Pharmaceuticals) and K-115 (Phase II, Kowa 
  Pharmaceutical). Other ROCK inhibitors Y-39983/SNJ-1656/
RKI-983 (Phase II, Senju and Novartis Pharmaceuticals) and 
Table 3 Ocular antihypertensive compounds discontinued or no longer in development
Compound Organization Highest development phase Notes
Anecortave acetate Alcon Pii; discontinued Cortisene devoid of glucocorticoid activity; 
anterior juxtascleral depot injection in the  
sub-Tenon’s space to reduce iOP in patients  
with glaucoma
AR-101 Aerie Planned Pi, never initiated Prostaglandin agonist
De-104 Santen/Ube Pii; discontinued Rho-kinase inhibitor; failed to meet 1° endpoint 
in Pi/ii trial
NCX-116;  
PF-03187207
Pfizer/NicOx PIII; discontinued (Pfizer) Nitric oxide donating PGF2α agonist; did not meet 
1° endpoint; Pfizer terminated PIII development 
in 2008; NicOx reacquired rights to NCX-116 in 
2009; see BOL-303259-X in Table 1
Olmesartan medoxomil;  
De-092; CS-088
Santen/Daiichi Sankyo Pii; discontinued Angiotensin ii AT1 antagonist; did not 
demonstrate clear dose response
Abbreviation: iOP, intraocular pressure.
Table 2 Novel ocular antihypertensive targets
Target/Compound Organization Highest development phase Notes
Actin
Latrunculin B; iNS-115644 inspire Pi Actin cytoskeleton modulator
Adenosine receptor
ATL-313 Santen Pi Adenosine A2A agonist
CF-101 Can-Fite Pii Adenosine A3 agonist; oral tablet
iNO-8875; PJ-875 inotek Pi/ii Adenosine A1 agonist
OPA-6566 Acucela/Otsuka Pi Adenosine A2A agonist
Cannabinoid receptor
SAD-448 Novartis Pi CB1/CB2 agonist
Corticosteroid 11-β-dehydrogenase isozyme 1
AZD-4017 Astra Zeneca Pii 11β HSD1 inhibitor; oral tablet
HPP-851 High Point/TransTech Pharma Pi 11β HSD1 inhibitor
Rho-kinase
AR-12286 Aerie Pii Rho kinase inhibitor
iNS-117548 inspire Pi Rho kinase inhibitor
K-115 Kowa Pii Rho kinase inhibitor
Y-39983; SNJ-1656; RKi-983 Senju/Novartis Pii Rho kinase inhibitor
Serotonin receptor
BvT.28949 Biovitrum Pii 5-HT2A antagonist; no development 
since 2008
Abbreviation: HSD1, hydroxysteroid dehydrogenase 1.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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INS-117548 (Phase I, Inspire Pharmaceuticals) are still under 
development, but have encountered efficacy and tolerability 
challenges. DE-104 (Phase I/II, Santen Pharmaceuticals and 
Ube Industries) development was discontinued in late 2010 
after its trial failed to meet the primary endpoint.
AR-12286 originated from a 6-aminoisoquinoline amide 
series and exhibits nanomolar potency against ROCK.50 Aerie 
Pharmaceuticals reported that AR-12286 is more selective 
than a competing ROCK inhibitor Y-39983/SNJ-1656/
RKI-983 (Senju and Novartis) with activity at 5 versus 25 of 
the off-target kinases that were tested.51 Topical AR-12286 
0.6% lowered IOP in ocular normotensive non-human 
primates primarily by increasing trabecular outflow.52 The 
company conducted a Phase IIa safety and efficacy clinical 
trial of AR-12286 at topical ophthalmic doses of 0.05%, 
0.1%, and 0.25%, once-daily followed by twice-daily over 
3 weeks, in patients with ocular hypertension or glaucoma 
(Trial ID: NCT00902200). AR-12286 lowered the IOP by 
4.4 mm Hg to a maximum of 6.8 mm Hg (28%) in patients 
treated with twice-daily 0.25% AR-12286, and the only 
adverse effect presented was trace to moderate conjunctival 
hyperemia.53 Aerie completed a Phase IIb, 28-day, safety and 
efficacy clinical trial of topical AR-12286 0.25% twice-daily 
or 0.5% once-daily versus latanoprost in 2010 (Trial ID: 
NCT01060579). Although AR-12286 is a relatively selective 
agent, its long-term tolerability profile and IOP-lowering 
efficacy in humans are unknown.
K-115, an isoquinolinesulfonamide compound, is a highly 
selective and potent (IC50 = 31 nM) Rho-kinase inhibitor.54 
It is in Phase II clinical development in patients with POAG 
or ocular hypertension by Kowa Pharmaceuticals (Trial 
IDs: JapicCTI-090708 and JapicCTI-101015). Preclinical 
  studies in monkeys showed 2.3 to 4.4 mm Hg decreases in 
IOP   following topical K-115 0.1%, 0.2%, 0.4% versus a 
2.5 mm Hg decrease for latanoprost 0.005%.54
Y-39983 (synonym RKI-983) is in Phase II clinical 
trials with Senju and Novartis Pharmaceuticals. Topical 
SNJ-1656 (an ophthalmic solution of Y-39983) reduced IOP 
by 3–4 mm Hg after single or repeated instillations (0.1%) 
and elicited trace to mild conjunctival hyperemia (0.003% 
to 0.1%) in healthy male volunteers evaluated in a 7-day 
Phase I clinical trial.55 Novartis conducted Phase I/II clini-
cal trials of topical RKI-983, twice-daily at 0.01%–0.05% 
(7 days) and 0.05%, 0.1% (29 days), versus vehicle and com-
parator latanoprost, once-daily at 0.005%, in patients with 
POAG or ocular hypertension (Trial IDs: CRKI983A2101/
NCT00515424; CRKI983A2201/NCT00846989). Results 
of the latter study showed RKI-983 0.1% reduced IOP by 
4.8 mm Hg (19.6%; day 29 average) and had an adverse 
events profile that included ocular disorders, most commonly 
mild to severe conjunctival hyperemia, followed by vascular 
disorders and other affected systems (Novartis Clinical Trial 
Results   Database). Thus, RKI-983 exhibited inferiority in 
IOP-lowering efficacy and tolerability compared to latano-
prost which had an average IOP decrease of 6.7 mm Hg 
(27.3%) on day 29.
Topically applied 0.05% Y-39983 or SNJ-1656 had similar 
IOP-lowering efficacies in human volunteers (2 mm Hg) and 
ocular normotensive cynomolgus monkeys (2.5 mm Hg).49,55 
In contrast, Y-39983 achieved substantially larger IOP reduc-
tions of 2.5 to 12 mm Hg at 0.003% to 0.05% in rabbits 
compared to decreases of 0.4 to 2.5 mm Hg in ocular nor-
motensive cynomolgus monkeys over the same dose range.49 
The dissimilar IOP responses may reflect species differences 
with respect to anatomy, physiology, pharmacokinetics, or 
the expression levels of ROCK and ROCK substrates in 
various ocular tissues. Toxicological studies indicated safety 
concerns, citing punctate subconjunctival hemorrhage and 
conjunctival hyperemia in rabbits and cynomolgus monkeys 
treated four-times daily with Y-39983 0.03% or 0.05%.49
INS-117548 is another ROCK inhibitor that had efficacy 
and tolerance concerns following a Phase I safety, toler-
ability, and ascending dose efficacy clinical trial in patients 
with early stage glaucoma or ocular hypertension (Trial ID: 
NCT00767793). Inspire Pharmaceuticals reported that twice-
daily INS-117548 produced mild reductions in IOP and some 
dose-related adverse effects, specifically ocular burning and 
stinging. The company is evaluating future directions in their 
glaucoma program.
Adenosine receptor
Adenosine is an endogenous purine nucleoside that modu-
lates physiological and pathophysiological processes by acti-
vating the G protein-coupled adenosine receptors.20,56,57 The 
four adenosine receptor subtypes that have been cloned are 
A1, A2A, A2B, and A3. Discerning which receptors are associ-
ated with IOP modulations has been difficult, since many of 
the earlier adenosine ligands evaluated are not highly selec-
tive for a particular receptor subtype. For example, adenosine 
agonist R-PIA has binding affinities (Ki) at human adenosine 
receptor subtypes of 2 nM (A1), 16 nM (A3), 860 nM (A2A), 
and 3,800–33,700 nM (A2B).56 It produced early dose-related 
IOP increases that were followed by later IOP decreases, an 
increase in total outflow facility (trabecular pathway), and 
modest changes in aqueous humor flow in conscious ocular 
normotensive cynomolgus monkeys.58 The mechanisms by Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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which adenosine receptor agonists increase conventional 
outflow have been hypothesized to involve shrinkage of cell 
volume and remodeling of the extracellular matrix following 
secretion of matrix metalloproteinases in human trabecular 
meshwork cells.59–62 Adenosine A3 antagonists may poten-
tially influence aqueous humor formation by preventing 
adenosine-induced activation of chloride channels in human 
nonpigmented ciliary epithelial cells.63,64 Therefore, adenos-
ine A1, A2A, A3 receptor agonists and A3 receptor antagonists 
have all been considered for IOP reduction.
The adenosine analogs that are currently in glaucoma 
clinical trials include INO-8875/PJ-875 (A1 agonist, 
Phase I/II, Inotek Pharmaceuticals), OPA-6566 (A2A agonist, 
Phase I planned in 2011, Acucela and Otsuka   Pharmaceutical), 
ATL-313 (A2A agonist, Phase I planned in 2011, Santen 
Pharmaceutical), and CF-101 (A3 agonist, Phase II, Can-Fite 
BioPharma). Compounds that target the A3 receptor as 
antagonists instead of agonists are in the preclinical stage.
INO-8875 (synonym PJ-875) is a potent agonist at A1 
receptors (Ki = 0.97 nM) that was shown to increase the facility 
of trabecular outflow in a perfused anterior segment model 
using porcine isolated corneo-scleral shells.65,66   Information 
regarding its activity at other receptors and effects on aqueous 
humor dynamics in living non-human primates has not been 
provided. Inotek Pharmaceuticals is conducting a Phase I/II 
dose-escalation clinical trial to evaluate the tolerability, safety, 
and efficacy of twice-daily topical INO-8875 in patients with 
ocular hypertension or POAG (Trial ID: NCT01123785). 
The company did not release details of an earlier Phase I/II 
single ascending ocular dose study, but reported that topical 
INO-8875 reduced IOP at the two highest doses tested. Pre-
clinical studies indicated statistically significant IOP decreases 
in ocular normotensive cynomolgus monkeys and pigmented 
rabbits given single topical INO-8875 doses of 10–1000 µg 
and 5–150 µg, respectively, with maximum IOP reductions 
of 20%–25% at 1–2 hours post-dose.66
The two adenosine A2A receptor agonists that have 
advanced to Phase I clinical trials with plans to start in 2011 
are OPA-6566 (Acucela and Otsuka Pharmaceutical) and 
ATL-313 (Santen Pharmaceutical). A2A receptors couple 
through G proteins to stimulate adenylyl cyclase, mediate 
vasodilatation, and may be down-regulated after chronic 
exposure to agonist.67,68 Therefore, conjunctival hyperemia 
and some loss of effectiveness over time are among the poten-
tial liabilities of topically administered A2A agonists.
CF-101 (generic name IB-MECA) is categorized by 
Can-Fite BioPharma as an A3 agonist. However, it has potent 
affinity (Ki) at human adenosine A3 (1.2–1.8 nM) as well as 
A1 (3.7-51 nM) receptors relative to A2A (2,500–2,900 nM) 
and A2B (54,000 nM) receptors.56,69 Can-Fite is conducting a 
Phase II safety and efficacy clinical trial of orally adminis-
tered CF-101 in patients with elevated IOP or POAG (Trial 
ID: NCT01033422). The rationale for conducting this study 
is based on an unexpected finding of a 1.1 mm Hg IOP 
decrease at week 12 during the safety assessment of orally 
administered CF-101 in a Phase II dry eye trial.70
Antagonists that target A3 receptors have also been 
proposed for IOP reduction, but drug candidates have not 
yet progressed to the clinical trials phase.69,71 One such 
compound is OT-7999, a potent and selective A3 antagonist 
(Ki = 0.61 nM) with Ki . 10,000 nM at the A1, A2A, and A2B 
receptors.72 OT-7999, at a single topical 1% dose, decreased 
IOP by 1.6 mm Hg in conscious male cynomolgus monkeys 
and was well tolerated.72
Angiotensin ii receptor
Angiotensin II is an endogenous peptide that elicits potent 
vasoconstriction and serves to modulate systemic blood 
pressure by activating the G protein-coupled angiotensin II 
receptor, type I (AT1).20,73,74 Olmesartan medoxomil is an 
orally administered AT1 receptor antagonist marketed for 
the treatment of systemic hypertension. In the eye, however, 
pharmacological effects of AT1 receptor antagonists on 
human cells and tissues have not been well characterized 
nor functionally correlated to IOP changes. AT1 antago-
nists may inhibit angiotensin II activities such as myosin 
light-chain phosphorylation in human trabecular meshwork 
cells.75 Losartan, an AT1 antagonist, was shown to block 
  angiotensin II activation of calcium sensitive large conduc-
tance potassium channels and cell volume loss in cultured 
cells of human nonpigmented ciliary epithelium.76
Topical olmesartan (synonyms DE-092, CS-088) was in 
early Phase II glaucoma clinical trials until late 2008, when 
Santen Pharmaceutical and Daiichi Sankyo Co terminated the 
study. Santen announced that DE-092 produced some IOP 
reductions; however the efficacy was insufficient with no clear 
dose-reponse relationship. The preclinical results support the 
clinical findings. Unilateral laser-induced ocular hypertensive 
cynomolgus monkeys treated with twice-daily topical CS-088 
at a 2% or 4% dose had IOP reductions of 5.3 mm Hg (15%) 
and 6.9 mm Hg (20%), respectively, on day 5 of the study.77 
Another study showed small reductions in outflow facility 
and increases in uveoscleral outflow of cynomolgus mon-
keys given topical twice-daily olmesartan 4%.78 The small 
IOP reductions were explained by opposing effects via the 
trabecular and uveoscleral outflow pathways.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Cannabinoid receptor
Endocannabinoids and the psychoactive ∆9-tetrahydrocan-
nabinol (∆9-THC), derived from Cannabis sativa (marijuana), 
are among the ligands that activate G protein-coupled can-
nabinoid receptors.79 CB1 and CB2 subtypes are two cannabi-
noid receptors that have been cloned and characterized.20 The 
medicinal uses of cannabis, including treatment for glaucoma 
via systemic exposure, have been known since ancient 
times.79–81 More recently, local mechanisms of IOP reduc-
tion were studied using WIN 55212–2, a potent synthetic 
cannabinoid CB1 and CB2 receptor agonist.80,82,83 In ocular 
normotensive cynomolgus monkeys, topically administered 
WIN 55212–2 0.5% lowered IOP by 3.4 mm Hg (19%) and 
reduced aqueous humor flow, but did not change the tono-
graphic outflow facility.82 Cannabinoid agonists can activate 
multiple signal transduction cascades that lead to activities 
such as relaxation and antimigration in human ocular tissues, 
but the functional associations with IOP modulation remain 
unclear.84–86
Novartis Pharmaceuticals conducted a Phase I clinical trial 
in 2007 on SAD-448, a CB1 and CB2 receptor agonist.87 The 
tolerability, safety, and efficacy of topical SAD-448 0.02% 
as a single drop and multiple drops (4 at 1 hour intervals) 
were assessed in subjects with ocular   hypertension (Trial ID: 
NCT00503360). SAD-448 reduced IOP by 2.3–2.4 mm Hg, 
which was not different from placebo, while the active com-
parator latanoprost 0.005% produced a 3.5 mm Hg decrease 
(Novartis Clinical Trial Results Database). No further devel-
opment has been reported since 2008.
Although not categorized as a CB1/CB2 agonist, 
palmitoylethanolamide (PEA) is an endogenous fatty acid 
ethanolamide that acts at cannabinoid-like receptors.20 The 
University of Catania (Italy) has evaluated Visimast® (PEA) 
as an adjunctive oral therapy in POAG patients under topical 
antihypertensive drug treatment (Trial ID: UMIN000002833). 
The mean IOP reductions were greater by 2.4–3.4 mm Hg in 
patients given oral PEA 300 mg, twice-daily, compared to 
placebo on days 30 and 60.88
Serotonin receptor
Serotonin (5-hydroxytryptamine, 5-HT) is a biogenic 
monoamine neurotransmitter that activates a large   family 
of   receptors in the G protein-coupled (5-HT1A,1B,1D,1E,1F, 
5-HT2A,2B,2C, 5-HT4, 5-HT5A,5B, 5-HT6, 5-HT7) and ligand-
gated ion channel (5-HT3) structural families.20,89 A few cases 
of elevated IOP or angle-closure glaucoma have been reported 
in patients treated with selective serotonin reuptake inhibi-
tors (SSRIs) which increase serotonin neurotransmission, 
suggesting a potential role for antagonists.90   Interestingly, 
preclinical studies indicated that topically applied 5-HT2 
agonists, but not 5-HT1A agonists or 5-HT2 antagonists, effec-
tively reduced the IOP of ocular normotensive and hyperten-
sive cynomolgus monkeys.91,92 A 5-HT2A,2B,2C receptor partial 
agonist, R-DOI (R-2,5-dimethoxy-4-iodoamphetamine), 
lowered IOP of cynomolgus monkeys primarily by a mecha-
nism of increasing uveoscleral outflow, but also caused a 
small increase in aqueous humor formation.92,93 R-DOI is a 
LSD (lysergic acid diethylamide)-like hallucinogen whose 
psychedelic effects are mediated by the 5-HT2A receptor.89,94 
Studies indicate that serotonin receptor regulation and sig-
nal transduction pathways are diverse and complex.89 For 
example, multiple scaffolding proteins and kinases regu-
late 5-HT2A receptor function, and both agonists and some 
antagonists induce receptor down-regulation.94,95 Therefore, 
5-HT2 agonists and antagonists have been proposed for IOP 
reduction. Some potential development obstacles pertaining 
to efficacy and adverse effects may be a lack of selectivity 
for the targeted serotonin receptor subtype and activity at 
non-serotonin receptors.
Swedish Orphan Biovitrum (Biovitrum) completed an 
exploratory Phase IIa clinical trial in 2008 on BVT.28949, 
a 5-HT2A receptor antagonist, in glaucoma or ocular hyper-
tensive patients (TrialTroveID: 070502). BVT.28949 (2 or 
7 mg/ml dose) twice-daily reduced IOP by 2.3 mm Hg (10%) 
after 4 weeks of treatment. Similarly, preclinical results of 
topical once-daily BVT.28949 (10 mM or 50 mM dose at 
10 µl volume) showed 1–3 mm Hg reductions in IOP of 
ocular normotensive cynomolgus monkeys.96 No further 
development of this compound has been reported.
Summary
Medical treatments to lower IOP are important for slowing 
the progression of glaucoma and delaying vision loss. New 
technological approaches for treating elevated IOP include 
siRNA and drug-eluting punctal plugs. The recent focus 
of new medical treatments for ocular hypertension and 
glaucoma is on novel targets for increasing aqueous humor 
outflow, particularly via the trabecular pathway. For first-line 
medical therapy, the new drug entities are compared to the 
benchmark standards and must demonstrate equivalent or 
superior safety and efficacy, as related to IOP reduction. 
The novel compounds evaluated in clinical trials include an 
actin polymerization inhibitor, Rho-associated protein kinase 
inhibitors, adenosine receptor agonists, an angiotensin II type 
1 receptor antagonist, cannabinoid receptor agonists, and a 
serotonin receptor antagonist. Results of the clinical trials to Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
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date suggest that these agents may need improvements to meet 
the safety and efficacy endpoints. Approval for adjunctive 
therapy is an alternative for compounds that do not achieve 
first-line status. Promising compounds are efficacious, exhibit 
favorable benefit-to-risk ratios, and have novel modes of 
action that are complementary to the marketed glaucoma 
medications. Although this review focused on IOP reduction 
and safety, compounds possessing properties that address the 
underlying disease process are highly desirable.
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